Rocio Gonzalez-Conejero

List of Publications by Year
in descending order

112 papers	2,957 citations	159585 30 h-index	206112 48 g-index
112 all docs	112 docs citations	112 times ranked	3453 citing authors

#	Article	IF	Citations
1	Prognostic and Predictive Effects of Tumor and Plasma miR-200c-3p in Locally Advanced and Metastatic Breast Cancer. Cancers, 2022, 14, 2390.	3.7	4
2	miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis. Haematologica, 2021, 106, 1636-1646.	3.5	39
3	Neutrophil extracellular traps and von Willebrand factor are allies that negatively influence COVIDâ€19 outcomes. Clinical and Translational Medicine, 2021, 11, e268.	4.0	15
4	MicroRNAs as New Regulators of Neutrophil Extracellular Trap Formation. International Journal of Molecular Sciences, 2021, 22, 2116.	4.1	17
5	The PI3KÎ´ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential. International Journal of Molecular Sciences, 2021, 22, 3304.	4.1	4
6	miR-146a in Cardiovascular Diseases and Sepsis: An Additional Burden in the Inflammatory Balance?. Thrombosis and Haemostasis, 2021, 121, 1138-1150.	3.4	11
7	Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists. Thrombosis Research, 2020, 185, 119-124.	1.7	20
8	Platelet activation and neutrophil extracellular trap (NET) formation in immune thrombocytopenia: is there an association?. Platelets, 2020, 31, 906-912.	2.3	8
9	Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation. Journal of Clinical Medicine, 2020, 9, 3645.	2.4	11
10	miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk. Leukemia, 2020, 34, 2648-2659.	7.2	18
11	MicroRNAs as potential regulators of platelet function and bleeding diatheses. Platelets, 2019, 30, 803-808.	2.3	14
12	Neutrophil extracellular trap components increase the expression of coagulation factors. Biomedical Reports, 2019, 10, 195-201.	2.0	13
13	Effect of <scp>CYP</scp>4F2,<scp>VKORC</scp>1, and <scp>CYP</scp>2C9 in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491.	4.7	23
14	Identification of Circulating microRNA Signatures As Potential Noninvasive Biomarkers for Prediction to Response to Extracorporeal Photoapheresis in Patients with Graft Versus Host Disease. Blood, 2019, 134, 4466-4466.	1.4	5
15	Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. European Journal of Clinical Investigation, 2018, 48, e12929.	3.4	5
16	microRNAs in the haemostatic system: More than witnesses of thromboembolic diseases?. Thrombosis Research, 2018, 166, 1-9.	1.7	23
17	MiR-146a Regulates Neutrophil Extracellular Trap Formation That Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 892-902.	2.4	66
18	Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome. Haematologica, 2018, 103, 908-918.	3.5	30

#	Article	IF	Citations
19	miR-146a deficiency in hematopoietic cells is not involved in the development of atherosclerosis. PLoS ONE, 2018, 13, e0198932.	2.5	16
20	rs2431697, a Polymorphism of Mir-146a, Is a Precozing Marker of Progression to Secondary Myelofibrosis: New Epigenetic Regulation of Jak/Stat3 Signaling. Blood, 2018, 132, 3072-3072.	1.4	0
21	Regulation of TFPIÎ± expression by miR-27a/b-3p in human endothelial cells under normal conditions and in response to androgens. Scientific Reports, 2017, 7, 43500.	3.3	20
22	Diagnostic potential of NETosis-derived products for disease activity, atherosclerosis and therapeutic effectiveness in Rheumatoid Arthritis patients. Journal of Autoimmunity, 2017, 82, 31-40.	6.5	82
23	Genotype-guided therapy improves initial acenocoumarol dosing. Thrombosis and Haemostasis, 2016, 115, 117-125.	3.4	10
24	MiRNA-Based Regulation of Hemostatic Factors through Hepatic Nuclear Factor-4 Alpha. PLoS ONE, 2016, 11, e0154751.	2.5	19
25	The role of microRNAâ€27a/b and microRNAâ€494 in estrogenâ€mediated downregulation of tissue factor pathway inhibitor Î±. Journal of Thrombosis and Haemostasis, 2016, 14, 1226-1237.	3.8	28
26	â€˜Atherothrombosis-associated microRNAs in Antiphospholipid syndrome and Systemic Lupus Erythematosus patientsâ€™. Scientific Reports, 2016, 6, 31375.	3.3	44
27	Uniparental disomy causes deficiencies of vitamin Kâ€dependent proteins. Journal of Thrombosis and Haemostasis, 2016, 14, 2410-2418.	3.8	6
28	CALU polymorphism A29809G affects calumenin availability involving vascular calcification. Journal of Molecular and Cellular Cardiology, 2015, 82, 218-227.	1.9	11
29	Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFÎ±. Arthritis Research and Therapy, 2015, 17, 49.	3.5	158
30	Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis. Human Reproduction, 2015, 30, 2292-2302.	0.9	51
31	Regulation of Coagulation Factor XI Expression by MicroRNAs in the Human Liver. PLoS ONE, 2014, 9, e111713.	2.5	34
32	Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. Thrombosis and Haemostasis, 2014, 112, 781-788.	3.4	36
33	Effect ofVKORC1, CYP2C9andCYP4F2genetic variants in early outcomes during acenocoumarol treatment. Pharmacogenomics, 2014, 15, 987-996.	1.3	8
34	Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas. Annals of Hematology, 2014, 93, 243-247.	1.8	13
35	Role of Genetic Polymorphisms in NFKB-Mediated Inflammatory Pathways in Response to Primary Chemoradiation Therapy for Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, 595-602.	0.8	15
36	Polymorphisms in xenobiotic metabolizing genes (EPHX1, NQO1 and PON1) in lymphoma susceptibility: a case control study. BMC Cancer, 2013, 13, 228.	2.6	13

#	Article	IF	Citations
37	Control of post-translational modifications in antithrombin during murine post-natal development by miR-200a. Journal of Biomedical Science, 2013, 20, 29.	7.0	10
38	Creating a genotype-based dosing algorithm for acenocoumarol steady dose. Thrombosis and Haemostasis, 2013, 109, 146-153.	3.4	30
39	Novel Associations of VKORC1 Variants with Higher Acenocoumarol Requirements. PLoS ONE, 2013, 8, e64469.	2.5	16
40	miR-133a Regulates Vitamin K 2,3-Epoxide Reductase Complex Subunit 1 (VKORC1), a Key Protein in the Vitamin K Cycle. Molecular Medicine, 2012, 18, 1466-1472.	4.4	36
41	Role of GSTT1 and M1 null genotypes as risk factors for Bâ€cell lymphoma: Influence of geographical factors and occupational exposure. Molecular Carcinogenesis, 2012, 51, 508-513.	2.7	9
42	Study of 18 functional hemostatic polymorphisms in mucocutaneous bleeding disorders. Annals of Hematology, 2010, 89, 1147-1154.	1.8	3
43	Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. Journal of Thrombosis and Haemostasis, 2010, 8, 1012-1017.	3.8	22
44	Influence of the F12-4 C>T polymorphism on hemostatic tests. Blood Coagulation and Fibrinolysis, 2010, 21, 632-639.	1.0	11
45	Synergism between factor XII â€“4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction. Thrombosis and Haemostasis, 2010, 104, 650-652.	3.4	2
46	Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. Annals of Medicine, 2010, 42, 562-575.	3.8	10
47	Plasma levels of Von Willebrand factor are increased in patients with hypertrophic cardiomyopathy. Thrombosis Research, 2010, 126, e46-e50.	1.7	16
48	CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis. Annals of Medicine, 2010, 42, 439-446.	3.8	12
49	Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. Thrombosis and Haemostasis, 2009, 101, 483-486.	3.4	37
50	Genotypeâ€“phenotype relationship for six common polymorphisms in genes affecting platelet function from 286 healthy subjects and 160 patients with mucocutaneous bleeding of unknown cause. British Journal of Haematology, 2009, 146, 95-103.	2.5	16
51	Pharmacogenetics in Cardiovascular Antithrombotic Therapy. Journal of the American College of Cardiology, 2009, 54, 1041-1057.	2.8	92
52	Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood, 2009, 113, 4977-4979.	1.4	73
53	Implications of Pharmacogenetics for Oral Anticoagulants Metabolism. Current Drug Metabolism, 2009, 10, 632-642.	1.2	15
54	Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. Thrombosis and Haemostasis, 2009, 101, 483-6.	3.4	4

#	Article	IF	Citations
55	Î³-glutamyl carboxylase R325Q polymorphism on the response of acenocoumarol. Thrombosis Research, 2008, 122, 429-431.	1.7	4
56	Factor VII â€“323 decanucleotide D/I polymorphism in atrial fibrillation: Implications for the prothrombotic state and stroke risk. Annals of Medicine, 2008, 40, 553-559.	3.8	14
57	The association of the Â1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Haematologica, 2007, 92, 513-518.	3.5	38
58	Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood, 2007, 109, 4258-4263.	1.4	104
59	A novel mutation in the antithrombin gene (insT 7429â€“30) causes superior mesenteric vein thrombosis. Thrombosis Research, 2007, 119, 793-796.	1.7	3
60	Coexistence of three genetic risk factors in a Spanish thrombophilic family: Factor V Leiden, prothrombin 20210 and a new type I antithrombin deficiency. Thrombosis and Haemostasis, 2007, 97, 153-155.	3.4	5
61	Protein Z/Z-dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis. British Journal of Haematology, 2007, 137, 99-108.	2.5	54
62	Prognostic value of annexin A5 ?1 C/T polymorphism in a long term follow-up after premature myocardial infarction. Journal of Thrombosis and Haemostasis, 2007, 5, 862-863.	3.8	6
63	The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. Journal of Thrombosis and Haemostasis, 2007, 5, 1701-1706.	3.8	34
64	Coexistence of three genetic risk factors in a Spanish thrombophilic family: Factor V Leiden, prothrombin 20210 and a new type I antithrombin deficiency. Thrombosis and Haemostasis, 2007, 97, 153-5.	3.4	2
65	Latent and polymeric antithrombin: clearance and potential thrombotic risk. Experimental Biology and Medicine, 2007, 232, 219-26.	2.4	11
66	A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. Blood, 2006, 108, 177-183.	1.4	58
67	Role of Fibrinogen Levels and Factor XIII V34L Polymorphism in Thrombolytic Therapy in Stroke Patients. Stroke, 2006, 37, 2288-2293.	2.0	54
68	Fluctuations in coagulation activity among patients with atrial fibrillation who are stably anticoagulated. Future Cardiology, 2006, 2, 197-203.	1.2	0
69	Protein Z-dependent protease inhibitor W303X mutation in venous thrombosis. British Journal of Haematology, 2005, 129, 561-562.	2.5	8
70	Synergistic association between hypercholesterolemia and the C46T factor XII polymorphism for developing premature myocardial infarction. Thrombosis and Haemostasis, 2005, 94, 1294-1299.	3.4	27
71	Biological Assessment of Aspirin Efficacy on Healthy Individuals. Stroke, 2005, 36, 276-280.	2.0	136
72	A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction. Journal of the American College of Cardiology, 2005, 45, 25-29.	2.8	27

#	Article	IF	Citations
73	Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction. Haematologica, 2005, 90, 421-3.	3.5	17
74	Homozygous Deficiency of Heparin Cofactor II. Circulation, 2004, 110, 1303-1307.	1.6	43
75	Platelet GP IIIa Polymorphism HPA-1 (PlA) Protects Against Subarachnoid Hemorrhage. Stroke, 2004, 35, 2282-2286.	2.0	24
76	Genetic variants of the extra-large stimulatory Gs protein alpha-subunit and risk of thrombotic and haemorrhagic disorders. British Journal of Haematology, 2004, 125, 621-628.	2.5	4
77	Mutations in the shutter region of antithrombin result in formation of disulfide-linked dimers and severe venous thrombosis. Journal of Thrombosis and Haemostasis, 2004, 2, 931-939.	3.8	53
78	Effect of factor VII -323 Del/Ins polymorphism on the daily variability of factor VIIc and INR in steady anticoagulated patients with acenocoumarol. Journal of Thrombosis and Haemostasis, 2004, 2, 2264-2265.	3.8	4
79	Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. Journal of Molecular and Cellular Cardiology, 2004, 37, 699-704.	1.9	36
80	Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction. American Heart Journal, 2004, 148, 602-605.	2.7	18
81	Mutation analysis of HPS1, the gene mutated in Hermansky-Pudlak syndrome, in patients with isolated platelet dense-granule deficiency. Haematologica, 2004, 89, 325-9.	3.5	5
82	Genetic Polymorphisms of Platelet Adhesive Molecules: Association with Breast Cancer Risk and Clinical Presentation. Breast Cancer Research and Treatment, 2003, 80, 145-154.	2.5	24
83	Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction. American Journal of Cardiology, 2003, 91, 1242-1245.	1.6	25
84	Detection of conformational transformation of antithrombin in blood with crossed immunoelectrophoresis: new application for a classical method. Translational Research, 2003, 142, 298-305.	2.3	21
85	Molecular, ultrastructural and functional characterization of a Spanish family with Hermansky-Pudlak syndrome: role of insC974 in platelet function and clinical relevance. British Journal of Haematology, 2003, 123, 132-138.	2.5	10
86	Polymorphisms of Platelet Adhesive Receptors: Do They Play a Role in Primary Intracerebral Hemorrhage?. Cerebrovascular Diseases, 2003, 15, 51-55.	1.7	22
87	The â^'1C>T mutation in the annexin A5gene does not affect plasma levels of annexin A5. Blood, 2003, 101, 4223-4224.	1.4	12
88	Platelet aggregation through prothrombinase activation induced by non-aggregant doses of platelet agonists. Blood Coagulation and Fibrinolysis, 2002, 13, 95-103.	1.0	3
89	Prothrombin A19911G and G20210A polymorphisms' role in thrombosis. British Journal of Haematology, 2002, 118, 610-614.	2.5	35
90	A common polymorphism in the annexin V Kozak sequence (-1C>T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients. Blood, 2002, 100, 2081-6.	1.4	11

#	Article	IF	Citations
91	Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage. Blood, 2001, 97, 2979-2982.	1.4	79
92	Polymorphisms of P-selectin glycoprotein ligand-1 are associated with neutrophil-platelet adhesion and with ischaemic cerebrovascular disease. British Journal of Haematology, 2001, 115, 969-976.	2.5	38
93	Role of Factor Xiii Val 34 Leu Polymorphism in Patients with Migraine. Cephalalgia, 2001, 21, 837-841.	3.9	12
94	Complejo plaquetario GP Ib/IX/V: papel fisiolÃ³gico. Journal of Physiology and Biochemistry, 2000, 56, 355-365.	3.0	10
95	The TFPI 536C â†'T Mutation Is not Associated with Increased Risk for Venous or Arterial Thrombosis. Thrombosis and Haemostasis, 2000, 83, 787-788.	3.4	30
96	Factor XIII Val34Leu polymorphism in primary intracerebral haemorrhage. The Hematology Journal, 2000, 1, 269-273.	1.4	10
97	Evaluation of Leukocyte–Depleted Platelet Concentrates Obtained by In–Line Filtration. Vox Sanguinis, 2000, 78, 235-241.	1.5	10
98	Prothrombotic Genetic Risk Factors in Patients With Coexisting Migraine and Ischemic Cerebrovascular Disease. Headache, 1999, 39, 486-489.	3.9	30
99	Quality assessment of platelet concentrates supplemented with second-messenger effectors. Transfusion, 1999, 39, 135-143.	1.6	28
100	The number of platelet glycoprotein Ia molecules is associated with the genetically linked 807 C/T and HPAâ€5 polymorphisms. Transfusion, 1999, 39, 372-378.	1.6	41
101	Autoaggression syndrome resembling acute graft-versus-host disease grade IV after autologous peripheral blood stem cell transplantation for breast cancer. Bone Marrow Transplantation, 1999, 23, 621-624.	2.4	13
102	Platelet Cryopreservation Using a Reduced Dimethyl Sulfoxide Concentration and Second-Messenger Effectors as Cryopreserving Solution. Cryobiology, 1999, 39, 1-12.	0.7	17
103	A Radioreceptor Assay for Mass Measurement of Inositol (1,4,5)-Trisphosphate Using Saponin-Permeabilized Outdated Human Platelets. Analytical Biochemistry, 1998, 256, 117-121.	2.4	2
104	New alleles of the platelet glycoprotein IbÎ± gene. British Journal of Haematology, 1998, 103, 997-1003.	2.5	22
105	Migraine and prothrombotic genetic risk factors. Cephalalgia, 1998, 18, 257-260.	3.9	32
106	Polymorphisms of Platelet Membrane Glycoprotein Ibîœ€ Associated With Arterial Thrombotic Disease. Blood, 1998, 92, 2771-2776.	1.4	168
107	Polymorphisms of Platelet Membrane Glycoprotein Ibîœ€ Associated With Arterial Thrombotic Disease. Blood, 1998, 92, 2771-2776.	1.4	4
108	Factor-V (Arg⁵⁰⁶â†'Gln) Mutation in Ischemic Cerebrovascular Disease. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1997, 27, 105-111.	0.3	3

#	Article	IF	Citations
109	The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. British Journal of Haematology, 1997, 99, 304-307.	2.5	92
110	Comparative Study of Three Methods to Detect Free Plasma Antiplatelet Antibodies. Acta Haematologica, 1996, 96, 135-139.	1.4	5
111	Association of autoantibodies against platelet glycoproteins Ib/IX and IIb/IIIa, and plateletâ€reactive antiâ€HIV antibodies in thrombocytopenic narcotic addicts. British Journal of Haematology, 1996, 93, 464-471.	2.5	16
112	Detection of Factor V Leiden from a Drop of Blood by PCR-SSCP. Thrombosis and Haemostasis, 1996, 76, 735-737.	3.4	39